RhumbLine Advisers
ALIM

RhumbLine Advisers’s Alimera Sciences ALIM Stock Holding History

RhumbLine Advisers’s Portfolio ALIM Stock Details ALIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20,394
Closed -$113K – 4377
2024
Q2 		$113K Buy
+20,394
New +$72.4K ﹤0.01% 3482
2016
Q2 		– Sell
-2,056
Closed -$54K – 3032
2016
Q1 		$54K Hold
2,056
– – ﹤0.01% 2957
2015
Q4 		$75K Buy
2,056
+190
+10% +$8.24K ﹤0.01% 2983
2015
Q3 		$62K Buy
1,866
+64
+4% +$3.6K ﹤0.01% 2984
2015
Q2 		$125K Buy
1,802
+44
+3% +$3.04K ﹤0.01% 2981
2015
Q1 		$132K Buy
1,758
+333
+23% +$26.2K ﹤0.01% 2911
2014
Q4 		$118K Buy
1,425
+35
+3% +$2.84K ﹤0.01% 2939
2014
Q3 		$113K Hold
1,390
– – ﹤0.01% 2912
2014
Q2 		$125K Buy
1,390
+365
+36% +$32.4K ﹤0.01% 2950
2014
Q1 		$121K Sell
1,025
-56
-5% -$5.44K ﹤0.01% 2896
2013
Q4 		$76K Sell
1,081
-6
-0.6% -$245 ﹤0.01% 2979
2013
Q3 		$61K Sell
1,087
-4
-0.4% -$251 ﹤0.01% 2961
2013
Q2 		$80K Buy
+1,091
New +$63K ﹤0.01% 3274

RhumbLine Advisers's ALIM Position: Q3 2024 in Review

RhumbLine Advisers sold out of Alimera Sciences (ALIM) in Q3 2024, closing a stake of 20,394 shares — an estimated $113K sold.

RhumbLine Advisers first reported a position in ALIM in Q2 2013 and held it in 13 quarters. The position peaked at $132K in Q1 2015. 0 funds tracked by Wall St. Rank hold ALIM as of Q3 2024.

  • RhumbLine Advisers reported no remaining Alimera Sciences position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 20,394 Alimera Sciences shares in Q3 2024, an estimated $113K.
  • RhumbLine Advisers first reported a position in Alimera Sciences in Q2 2013 and held it in 13 quarters.
  • RhumbLine Advisers's Alimera Sciences position peaked at $132K in Q1 2015.
  • 0 funds tracked by Wall St. Rank held Alimera Sciences as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.